PT  - JOURNAL ARTICLE
AU  - Kurashima, Kazuyoshi
AU  - Kagiyama, Naho
AU  - Ishiguro, Takashi
AU  - Takaku, Yotaro
AU  - Nakajima, Hiromi
AU  - Shibata, Shun
AU  - Matsui, Yuma
AU  - Takano, Kenji
AU  - Isono, Taisuke
AU  - Nishida, Takashi
AU  - Kawate, Eriko
AU  - Hosoda, Chiaki
AU  - Kobayashi, Yoichi
AU  - Takayanagi, Noboru
AU  - Yanagisawa, Tsutomu
TI  - IgG antibody seroconversion and the clinical progression of COVID-19 pneumonia: A retrospective, cohort study
AID  - 10.1101/2020.07.16.20154088
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.16.20154088
4099  - http://medrxiv.org/content/early/2020/07/17/2020.07.16.20154088.short
4100  - http://medrxiv.org/content/early/2020/07/17/2020.07.16.20154088.full
AB  - Background Coronavirus Disease 2019 (COVID-19) causes severe acute respiratory failure. Antibody-dependent enhancement (ADE) is known as the mechanism for severe forms of other coronavirus diseases. The clinical progression of COVID-19 before and after IgG antibody seroconversion was investigated.Methods Fifty-three patients with reverse transcriptase PCR (RT-PCT)-confirmed COVID-19 viral pneumonia with or without respiratory failure were retrospectively investigated. The timing of the first IgG antibody against SARS-CoV-2-positive date, as well as changes of C-reactive protein (CRP) as an inflammatory marker and blood lymphocyte numbers, was assessed using serial preserved blood samples.Findings Ten patients recovered without oxygen therapy (mild/moderate group), 32 patients had hypoxemia and recovered with antiviral drugs (severe/non-ICU group), and 11 patients had severe respiratory failure and were treated in the ICU (6 of them died; critical/ICU group). The first IgG-positive date (day 0) was observed from 5 to 18 days from the onset of disease. At day 0, a CRP peak was observed in the severe and critical groups, whereas there was no synchronized CRP peak on day 0 in the mild/moderate group. In the severe/non-ICU group, the blood lymphocyte number increased (P=0.0007) and CRP decreased (P=0.0007) after day 0, whereas CRP did not decrease and the blood lymphocyte number further decreased (P=0.0370) in the critical/ICU group.Interpretation The respiratory failure due to COVID-19 viral pneumonia observed in week 2 may be related to an antibody-related mechanism rather than uncontrolled viral replication. In the critical form of COVID-19, inflammation was sustained after IgG seroconversion.Funding noneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThere is no funding supported in the work presented.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Saitama Cardiovascular and Respiratory Center (IRB No. 2019062).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the manuscript.